Ocular drug delivery for glaucoma management

Pharmaceutics

Volumn 4, Issue 1, 2012, Pages 197-211

  Gooch, Nathan ^b   Molokhia, Sarah A ^c   Condie, Russell ^b   Burr, Randon Michael ^a   Archer, Bonnie ^a   Ambati, Balamurali K ^a   Wirostko, Barbara ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Utah   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Drug delivery; Glaucoma; Inserts; IOP; Polymer; Punctal plug; Sustained release

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; ANECORTAVE; ANTIGLAUCOMA AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZALKONIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DEXAMETHASONE; EYE DROPS; HYDROXYPROPYLCELLULOSE; LATANOPROST; LIPOSOME; MICROSPHERE; NANOSPHERE; PILOCARPINE; POLYCAPROLACTONE; POLYGLACTIN; PROSTAGLANDIN DERIVATIVE; SILICONE; SMALL INTERFERING RNA; TIMOLOL;

CONTACT LENS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPNEA; EYE BURNING; FATIGUE; GEL; GLAUCOMA; HEART DISEASE; HUMAN; HYDROGEL; HYPOTENSION; INCISION; INFUSION PUMP; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; LUNG DISEASE; MEAN RESIDENCE TIME; NONHUMAN; OPEN ANGLE GLAUCOMA; OPHTHALMIC INSERT; PATIENT COMPLIANCE; PUMP DESIGN; PUNCTAL PLUG; RETINA MACULA EDEMA; REVIEW; SUSTAINED RELEASE PREPARATION; SYSTEMIC DISEASE; TACHYCARDIA; UVEITIS;

EID: 84858837854     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics4010197     Document Type: Review

References (66)

1. Cedrone, C.; Mancino, R.; Cerulli, A.; Cesareo, M.; Nucci, C. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog. Brain Res. 2008, 173, 3-14.
2. Quigley, H.A.; Broman, A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90 (3), 262-267.
3. Friedman, D.S.; Wolfs, R.C.; O'Colmain, B.J.; Klein, B.E.; Taylor, H.R.; West, S.; Leske, M.C.; Mitchell, P.; Congdon, N.; Kempen, J. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004, 122 (4), 532-538.
4. National Eye Institute, N.I.o.H. National Eye Institute. Available online: http://www.nei.nih.gov/ (accessed on 4 November 2011).
5. Prevent Blindness America. Prevent Blindness America. 2011; Available online: http://www.preventblindness.org/ (accessed on 4 November 2011).
6. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am. J. Ophthalmol. 2000, 130 (4), 429-440.
7. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 1998, 126 (4), 498-505.
8. Heijl, A.; Leske, M.C.; Bengtsson, B.; Hyman, L.; Hussein, M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002, 120 (10), 1268-1279.
9. Kass, M.A.; Heuer, D.K.; Higginbotham, E.J.; Johnson, C.A.; Keltner, J.L.; Miller, J.P.; Parrish, R.K.; Wilson, M.R.; Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120 (6), 701-713; discussion 829-830.
10. Medeiros, F.A.; Weinreb, R.N.; Zangwill, L.M.; Alencar, L.M.; Sample, P.A.; Vasile, C.; Bowd, C. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology 2008, 115 (6), 934-940.
11. Musch, D.C.; Gillespie, B.W.; Niziol, L.M.; Lichter, P.R.; Varma, R. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2011, 118 (9), 1766-1773.
12. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd ed.; Editrice Dogma S.r.l.: Savona, Italy, 2008. Available online: http://www.eugs.org/eng/aims.asp (accessed on 2 September 2011).
13. ® Guidelines 2010 Available online: http://one.aao.org/ce/practiceguidelines/ppp_content.aspx? cid=e2387c8a-e51c-4c21-be20-c30fbf4f3260/ (accessed on 15 November 2011).
14. Robin, A.; Grover, D.S. Compliance and adherence in glaucoma management. Indian J. Ophthalmol. 2011, 59 (Suppl.), S93-S96.
15. Leske, M.C.; Heijl, A.; Hyman, L.; Bengtsson, B.; Dong, L.; Yang, Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007, 114 (11), 1965-1972.
16. Tsai, J.C.; McClure, C.A.; Ramos, S.E.; Schlundt, D.G.; Pichert, J.W. Compliance barriers in glaucoma: a systematic classification. J. Glaucoma 2003. 12 (5), 393-398.
17. Walt, J.G.; Wilensky, J.T.; Fiscella, R.; Chiang, T.H.; Guckian, A. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis. Clin. Drug Investig. 2007, 27 (12), 819-825.
18. Schwartz, G.F.; Platt, R.; Reardon, G.; Mychaskiw, M.A. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007, 114 (4), 648-652.
19. Wilensky, J.; Fiscella, R.G.; Carlson, A.M.; Morris, L.S.; Walt, J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am. J. Ophthalmol. 2006, 141 (1 Suppl.), S28-S33.
20. Hennessy, A.L.; Katz, J.; Covert, D.; Kelly, C.A.; Suan, E.P.; Speicher, M.A.; Sund, N.J.; Robin, A.L. A Video Study of Drop Instillation in Both Glaucoma and Retina Patients with Visual Impairment. Am. J. Ophthalmol. 2011, 152 (6), 982-988.
21. Robin, A.L.; Novack, G.D.; Covert, D.W.; Crockett, R.S.; Marcic, T.S. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol. 2007, 144 (4), 533-540.
22. Hennessy, A.L.; Katz, J.; Covert, D.; Protzko, C.; Robin, A.L. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology 2010, 117 (12), 2345-2352.
23. Zimmerman, T.J.; Hahn, S.R.; Gelb, L.; Tan, H.; Kim, E.E. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J. Ocul. Pharmacol. Ther. 2009, 25 (2), 145-152.
24. Visiongain. Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics-2009-2023; Visiongain, Ltd: London, UK, 2009; p. 148.
25. Coleman, A.L.; Caprioli, J. The logic behind target intraocular pressure. Am. J. Ophthalmol. 2009, 147 (3), 379-380.
26. Bean, G.W.; Camras, C.B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv. Ophthalmol. 2008, 53 (Suppl. 1), S69-S84.
27. Kreuter, J. Particulates (nanoparticles and Microparticles). In Ophthalmic Drug Delivery Systems; Mitra, A.K., Ed.; Marcel Dekker: New York, NY, USA, 1993; pp. 275-285.
28. Fattal, E.; Bochot, A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 2006, 58 (11), 1203-1223.
29. Monem, A.S.; Ali, F.M.; Ismail, M.W. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int. J. Pharm. 2000, 198 (1), 29-38.
30. Short, B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 2008, 36 (1), 49-62
31. Saati, S.; Lo, R.; Li, P.Y.; Meng, E.; Varma, R.; Humayun, M.S. Mini drug pump for ophthalmic use. Trans. Am. Ophthalmol. Soc. 2009, 107, 60-70.
32. Kuno, N.; Fujii, S. Recent Advances in Ocular Drug Delivery Systems. Polymers 2011, 3 (1), 193-211.
33. Gulsen, D.; Chauhan, A. Ophthalmic drug delivery through contact lenses. Invest. Ophthalmol. Vis. Sci. 2004, 45 (7), 2342-2347.
34. Ciolino, J.B.; Hoare, T.R.; Iwata, N.G.; Behlau, I.; Dohlman, C.H.; Langer, R.; Kohane, D.S. A drug-eluting contact lens. Invest. Ophthalmol. Vis. Sci. 2009, 50 (7), 3346-3352.
35. Ciolino, J.B.; Hudson, S.P.; Mobbs, A.N.; Hoare, T.R.; Iwata, N.G.; Fink, G.R.; Kohane, D.S. A prototype antifungal contact lens. Invest. Ophthalmol. Vis. Sci. 2011, 52 (9), 6286-6291.
36. Natarajan, J.V.; Chattopadhyay, S.; Ang, M.; Darwitan, A.; Foo, S.; Zhen, M.; Koo, M.; Wong, T.T.; Venkatraman, S.S. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One 2011, 6 (9), e24513.
37. Bertram, J.P.; Saluja, S.S.; McKain, J.; Lavik, E.B. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months. J. Microencapsul. 2009, 26 (1), 18-26.
38. Horsley, M.B.; Kahook, M.Y. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin. Ophthalmol. 2009, 3, 291-295.
39. Henry, J.C.; Peace, J.H.; Stewart, J.A.; Stewart, W.C. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin. Ophthalmol. 2008, 2 (3), 613-621.
40. Islam, S. Lipophilic and Hydrophilic Drug Loaded PLA/PLGA In Situ Implants: Studies on Thermal Behavior of Drug & Polymer and Observation of Parameters Influencing Drug Burst Release With Corresponding Effects on Loading Efficiency & Morphology of Implants. Int. J. Pharm. Pharm. Sci. 2011, 3 (3), 181-188.
41. Kadam, R.S.; Cheruvu, N.P.; Edelhauser, H.F.; Kompella, U.B. Sclera-choroid-RPE transport of eight beta-blockers in human, bovine, porcine, rabbit, and rat models. Invest. Ophthalmol. Vis. Sci. 2011, 52 (8), 5387-5399.
42. Frank, A.; Rath, S.K.; Venkatraman, S.S. Controlled release from bioerodible polymers: effect of drug type and polymer composition. J. Control. Release 2005, 102 (2), 333-344.
43. Fu, K.; Harrell, R.; Zinski, K.; Um, C.; Jaklenec, A.; Frazier, J.; Lotan, N.; Burke, P.; Klibanov, A.M.; Langer, R. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J. Pharm. Sci. 2003, 92 (8), 1582-1591.
44. Peng, Y.; Ang, M.; Foo, S.; Lee, W.S.; Ma, Z.; Venkatraman, S.S.; Wong, T.T. Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes. PLoS One 2011, 6 (7), e22507.
45. Borgia, M.J.; Chaouk, H.; Cui, H.; Laredo, W.; Li, Z.; Nathan, A.; II, M.J.T. Punctal Plugs for the Delivery of Active Agents; Johnson & Johnson: New Brunswick, NJ, USA, 2008; p. 10.
46. The Eye Digest. Punctal Plugs. 05/19/2009. Available online: http://www.agingeye.net/dryeyes/ plugsetc.php (accessed on 1 November 2011).
47. Chauhan, A.; Zhu, H. Dry Eye Treatment by Puncta Plugs. University of Florida Research Foundation: Gainsville, FL, US, 2010; p. 15.
48. Rodstrom, T.R.; Smith, L.; Tian, Y.; Allen, D.; Weiner, L.; Bakshi, S. Punctal Plugs and Methods of Delivering Therapeutic Agents; Alcon Research, Ldt: Fort Worth, TX, US, 2008; p. 13.
49. Pollack, I.P.; Quigley, H.A.; Harbin, T.S. The Ocusert pilocarpine system: advantages and disadvantages. South Med. J. 1976, 69 (10), 1296-1298.
50. University of Kentucky Clinical Trial, Safety Study of Latanoprost Slow Release Insert (Latanoprost SR). 2010. Available online: ClinicalTrials.gov (accessed on 15 December 2011).
51. Aerie Pharmaceuticals. Aerie Pharmaceuticals, Inc. 2011; Available online: http://www.aeriepharma.com/ (accessed on 15 December 2011).
52. Kopezynski, C.; Lin, C.-W.; Sutay, C. Drug Delivery Devices for Delivery of Therapeutic Agents. US 2010/0158980 A1, 18 December 2010.
53. Krupin, T.; Liebmann, J.M.; Greenfield, D.S.; Ritch, R.; Gardiner, S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am. J. Ophthalmol. 2011, 151 (4), 671-681.
54. Allergan Clinical Trial, Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD). 2008. Available online: ClinicalTrials.gov (accessed on 4 November 2011).
55. Hennessy, A.L.; Robin, A.L. Anecortave Acetate: A New Approach for the Medical Treatment of Glaucoma. In the Glaucome Book: A Practical, Evidence-Based Approach to Patient Care; Schanknow, P.N., Samples, J.R., Eds.; Springer: New York, NY, USA, 2010; pp. 988-994.
56. Robin, A.L.; Clark, A.F.; Covert, D.W.; Krueger, S.; Bergamini, M.V.; Landry, T.A.; Dickerson, J.E., Jr.; Scheib, S.A.; Realini, T.; Defaller, J.M. et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am. J. Ophthalmol. 2009, 147 (1), 45-50 e2.
57. Smit, B. Anecortave Acetate for Steroid-Induced OHT. In Glaucoma Today; Bryn Mawr Communications LLC: Wayne, PA, USA, 2010; pp. 43-44
58. Alcon Inc. Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction. Business Wire: press release, Huenenberg, Switzerland, 2 July 2009.
59. Stewart, W.C.; Konstas, A.G.; Nelson, L.A.; Kruft, B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008, 115 (7), 1117-1122 e1.
60. Caprioli, J.; Coleman, A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 2008, 115 (7), 1123-1129 e3.
61. Caprioli, J.; Varma, R. Intraocular pressure: modulation as treatment for glaucoma. Am. J. Ophthalmol. 2011, 152 (3), 340-344 e2.
62. Wu, A.W.; Snyder, C.; Clancy, C.M.; Steinwachs, D.M. Adding the patient perspective to comparative effectiveness research. Health Aff. (Millwood) 2010, 29 (10), 1863-1871.
63. Kymes, S.M.; Plotzke, M.R.; Li, J.Z.; Nichol, M.B.; Wu, J.; Fain, J. The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach. Am. J. Ophthalmol. 2010, 150 (1), 74-81.
64. Traverso, C.E.; Walt, J.G.; Kelly, S.P.; Hommer, A.H.; Bron, A.M.; Denis, P.; Nordmann, J.P.; Renard, J.P.; Bayer, A.; Grehn, F. et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br. J. Ophthalmol. 2005, 89 (10), 1245-1249.
65. Garaci, F.G.; Bolacchi, F.; Cerulli, A.; Melis, M.; Spano, A.; Cedrone, C.; Floris, R.; Simonetti, G.; Nucci, C. Optic nerve and optic radiation neurodegeneration in patients with glaucoma: in vivo analysis with 3-T diffusion-tensor MR imaging. Radiology 2009, 252 (2), 496-501.
66. Yucel, Y.H.; Zhang, Q.; Weinreb, R.N.; Kaufman, P.L.; Gupta, N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog. Retin Eye Res. 2003, 22 (4), 465-481.